

## References

- BPOM RI. (2022). Explanation from BPOM RI Regarding the Issue of Syrup Medication Which Has the Risk of Containing Ethylene Glycol (EG) and Diethylene Glycol (DEG) Contamination. Retrieved from <https://www.pom.go.id/penjelasan-publik/penjelasan-bpom-ri-tentang-isu-obat-sirup-yang-berisiko-mengandung-cemaran-etilen-glikol-eg-dan-dietilen-glikol-deg>
- Ferreira, D. F. L. (2014). ICH Q8/Q9/Q10 Guidelines: Changing Paradigm in Pharmaceutical Development. Retrieved from [https://estudogeral.uc.pt/bitstream/10316/28095/1/EN\\_Diogo%20Ferreira\\_ICH%20Q8%2C%20Q9%20and%20Q10%20Changing%20Paradigm%20in%20Pharmaceutical%20Development\\_08-2014.pdf](https://estudogeral.uc.pt/bitstream/10316/28095/1/EN_Diogo%20Ferreira_ICH%20Q8%2C%20Q9%20and%20Q10%20Changing%20Paradigm%20in%20Pharmaceutical%20Development_08-2014.pdf)
- ECA. (2020). What Are the GMP Requirements for Supplier Qualification? Retrieved from <http://surl.li/lvbxxy>
- EMA. (2000). ICH Topic Q 7 Good Manufacturing Practice for Active Pharmaceutical Ingredients . Retrieved from [https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-7-good-manufacturing-practice-active-pharmaceutical-ingredients-step-5\\_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-7-good-manufacturing-practice-active-pharmaceutical-ingredients-step-5_en.pdf)
- Meghan. (2022). Supplier Qualification – Ensuring High Quality Suppliers. Retrieved from <https://www.pharmout.net/supplier-qualification-ensuring-high-quality-suppliers/>
- Milton, A. (2022). Buying and Selling Volume. Retrieved from Buying and Selling Volume
- Paul, S. K., & Azeem, A. (2009). Defects Identification and Analysis of a Pharmaceutical Product Using Pareto and Cause-Effect Analysis. doi:10.13140/RG.2.1.2328.9364
- Phapros. (2023). Retrieved from <https://www.phapros.co.id/>
- Penn, R. (2022). Risk Priority Number (RPN). Retrieved from <http://surl.li/lvbyu>
- Yarmohammadian, M. H., Rezaei, F., Haghshenas, A., Fallah, A., & Ferdosi, M. (2018). Revised risk priority number in failure mode and effects analysis model from the perspective of healthcare system. *International Journal of Preventive Medicine*, 9(1), 7. doi:10.4103/2008-7802.224046